Insilico Medicine struck an R&D collaboration with Servier valued up to $888 million to discover and develop oncology therapies using Insilico’s AI discovery platforms. The agreement follows Insilico’s recent Hong Kong IPO and will couple the company’s generative AI and discovery engines with Servier’s clinical and development expertise. Insilico will receive upfront and near‑term payments and stands to gain milestone and commercial upside if candidates progress. The partnership underscores continued pharma interest in AI‑driven target identification and preclinical candidate generation across oncology.